Improvement of coronary vasodilator capacity by lipid-lowering therapy in patients with angina pectoris, reduced coronary reserve and moderate LDL- hypercholesterolemia;Verbesserung der koronaren vasodilatationskapazitat durch medikamentose lipid-senkung bei patienten im fruhstadium der koronaren atherosklerose mit eingeschrankter koronarreserve und massiggradiger LDL-hypercholesterinamie

Zeitschrift fur Kardiologie

Volumn 87, Issue SUPPL. 2, 1998, Pages 136-144

  Baller, D ^a   Gleichmann, U ^a   Notohamiprodjo, G ^a   Weise, R ^a   Holzinger, J ^a   Montanus, H ^a   Betker, S ^a   Lehmann, J ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; DIPYRIDAMOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; DIAGNOSTIC AGENT;

ADULT; ANGINA PECTORIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DISEASE COURSE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; DRUG EFFECT; EXERCISE TEST; FOLLOW UP; LOW FAT DIET; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; VASODILATATION;

ADULT; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DIET, FAT-RESTRICTED; DIPYRIDAMOLE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME; VASODILATION;

EID: 0032237606     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Anderson TA, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493
2. Andrews TC, Raby K, Barry J, Cameron L, Naimi BA, Allred E, Ganz P, Selwyn AP (1997) Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 95: 324-328
3. 2 supply by the DPTI/STTI ratio under maximal coronary dilation. Basic Res Cardiol 74: 378-388
4. Baller D (1985) Coronary vascular reserve under atrial and ventricular pacing. In: Gomez FP (ed) Proceedings of the 3rd european symposium on cardiac pacing. Editorial group, Madrid, 535-542
5. Baller D (1997) Ist die koronare Herzkrankheit eine chronisch-entzündliche Erkrankung? Klinik & Forschung 3: 45-47
6. Baller D, Gleichmann U, Notohamiprodjo G, Holzinger J, Heise R, Kromer M, Montanus H (1997) Is the cholesterol-associated reduction of coronary vasodilator capacity reversibel after intensive lipid lowering? Noninvasive control with positron emission tomography after six months. J Clin Invest 27 (Suppl 1): A 28/155
7. Baller D, Seggewiß H, Gleichmann U, Weise R, Holzinger J, Faber L, Betker S, Bogunovic N, Notohamiprodjo G (1997) Assessment of regional coronary flow reserve in 30 patients with hypertrophic obstructive cardiomyopathy using positron emission tomography (PET). Europ Heart J 18 (Abstr Suppl): 377
8. Baller D, Weise R, Holzinger J, Montanus H, Kromer M, Gleichmann U, Notohamiprodjo G (1997) Bestimmung der koronaren Vasodilatationskapazität bei Patienten mit LDL-Hypercholesterinämie, Angina pectoris und weitgehend normalem Koronarangiogramm mittels N-13-Ammoniak und Positronenemissionstomographie. Nuklearmedizin 36: A48-V134
9. Baller D, Wolpers HG, Zipfel J, Bretschneider HJ, Hellige G (1988) Comparison of the effects of right atrial, right ventricular pacing and atrioventricular sequential pacing on myocardial oxygen consumption and cardiac efficiency. PACE 11: 394-403
10. Bassenge E, Busse R (1988) Endothelial modulation of coronary tone. Prog Cardiovasc Dis 30: 349-380
11. Bretschneider HJ, Frank A, Bernard U, Kochsiek K, Scheler F (1959) Die Wirkung eines Pyrimidopyrimidin-Derivates auf die Sauerstoff-Versorgung des Herzmuskels. Arzneim Forsch 9: 49-59
12. Bretschneider HJ (1963) Pharmakotherapie koronarer Durchblutungsstörungen mit kreislaufwirksamen Substanzen. Verh Dtsch Ges Inn Med 69: 583-599
13. Brown GB, Zhao XQ, Sacco DE, Albers JJ (1993) Lipid lowering and plaque regression - new insights into prevention of plaque disruption and clinical events in coronary artery disease. Circulation 87: 1781-1791
14. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire M, Schwaiger M (1994) Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 90: 808-817
15. Drexler H, Zeiher AM (1991) Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension 18 (Suppl II): II-90-II-99
16. Drexler H, Zeiher AM, Meinzer K, Just J (1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 338: 1546-1550
17. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A (1994) Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89: 2519-2524
18. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A (1993) Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 328: 1659-1664
19. Galle J, Bassenge E, Busse R (1990) Oxidized low-density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res 66: 1287-1293
20. Galle J, Mülsch A, Busse R, Bassenge E (1991) Effects of native and oxidized low density lipoproteins on formation and inactivation of EDRF. Arterioscl Thromb 11: 198-203
21. Gleichmann U, Baller D (1997) Antihypertensive Therapie bei Herzerkrankungen. In: Klaus D (Hrsg.) Manuale hypertonologicum. Dustri-Verlag, Deisenhofen, X-2:1-X-2:21
22. Gleichmann U, Mannebach H, Gleichmann S (1991) Kontrolle von Risikofaktoren bei dokumentierter koronarer Herzkrankheit. In: Gleichmann U, Mannebach H, Gleichmann S, Held K (Hrsg.) Herausforderung Atherosklerose in den 90ern. Steinkopf Verlag, Darmstadt, S 35-51
23. Gleichmann U, Ohlmeier H, Mannebach H, Faßbender D (1981) Hemodynamics and prognosis of patients with angina pectoris without coronary heart disease (Syndrome X). Cardiology 68 (Suppl 2): 108-113
24. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ (1994) Short term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing endothelium. Circulation 89: 1530-1538
25. Harrison DG, Ohara Y (1995) Physiologic consequences of increased vascular oxidant stress in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Physiol 75: B75-B81
26. Holtz J, Krivokuca M, Allgeier J, Goetz RM (1991) Dipyridamole-recruitable coronary reserve is attenuated by suppression of nitric oxide synthesis in rats. Eur Heart J 12 (Suppl 4): 525
27. Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE (1990) Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomography imaging. J Am Coll Cardiol 15: 1032-1042
28. Kübler W, Hautman M (1992) Syndrome X: an early form of cardiomyopathy? Coronary Artery Disease 3: 570-573
29. Leung WH, Lau CP, Wong CK (1993): Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 341: 1496-1500
30. Liao JK, Shin WS, Lee WY, Clark SL (1995) Oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270: 319-324
31. Lupi A, Buffon A, Finocchiario ML, Conti E, Maseri A, Crea F (1997) Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J 18: 614-617
32. Montanus H, Baller D, Gleichmann U, Notohamiprodjo G, Holzinger J, Weise R, Kromer M, Miche E, Lehmann J (1997) Effekte einer vierwöchigen Statinmedikation bei Patienten mit Angina pectoris, LDL-Hypercholesterinämie und eingeschränkter Koronarreserve trotz weitgehend normalem Koronarangiogramm. Z Kardiol 86 (Suppl 2): 355/A 1284
33. Motz W, Vogt M, Rabenau O, Scheler S, Lückhoff A, Strauer BE (1991) Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol 68: 996-1003
34. Muzik O, Beanlands R, Hutchins GD, Mangner TJ, Nguyen N, Schwaiger M (1993) Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 34: 83-91
35. Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551
36. Opherk D, Zebe H, Weihe E, Mall G, Mäurer W, Gravert B, Mehmel HC, Schuler G, Kübler W (1981) Das Syndrom pektanginöser Beschwerden bei Patienten mit normalem Koronarangiogramm (Syndrom X). Dtsch med Wschr 106: 1686-1691
37. Opherk D, Schwarz F, Mall G, Manthey J, Baller D, Kübler W (1983) Coronary dilator capacity in idiopathic dilated cardiomyopathy: analysis of 16 patients. Am J Cardiol 51: 1657-1662
38. Opherk D, Mall G, Zebe H, Schwarz F, Weihe E, Manthey J, Kübler W (1984) Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation 69: 1-7
39. Ornish D, Brown SE, Scherwitz LW (1990) Can life-style changes reverse coronary heart disease? - The lifestyle Heart Trial. Lancet 336: 129-133
40. Reddy KG, Nair NR, Sheehan HM, Hodgson JM (1994) Evidence that endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 23: 833-843
41. Roubanyi G, Vanhoutte PM (1985) Endothelial-removal decreases relaxtions of canine coronary arteries caused by adrenergic agonists and adenosine. J Cardiovasc Pharmacol 7: 139-144
42. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009
43. Scandinavian simvastatin survival study group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344: 1383-1389
44. Schuler G, Schlierf G, Wirth A, Mautner H-P, Scheurlen H, Thumm M, Roth H, Schwarz F, Kohlmeier M, Mehmel HC, Kübler W (1988) Low fat diet and regular, supervised physical exercise in patients with symptomatic coronary artery disease. Reduction of exercise induced myocardial ischemia. Circulation 77: 172-181
45. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE (1993) Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 88: 993-1003
46. Seidel D (1993) Risikofaktoren der Atherogenese. Mechanismen ihrer Wirkung und klinische Bewertung. Deutsches Ärzteblatt 90: 61714-1723
47. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, Mckillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307
48. Strauer BE (1979) Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol 44: 999-1006
49. Strauer BE (1990) The significance of coronary reserve in clinical heart disease. J Am Coll Cardiol 15: 775-783
50. Tauchert M, Hilger HH (1979) Application of the coronary reserve concept to the study of myocardial perfusion In: Schaper W (ed) The pathophysiology of myocardial perfusion. Elsevier Science BV, Biomedical Devision, Netherlands, pp 141-167
51. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487
52. Zeiher AM, Drexler H, Saurbier H, Just H (1993) Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest 92: 652-662
53. Zeiher AM, Drexler H, Wollschläger H, Just H (1991) Modulation of coronary vasomotor tone. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83: 391-401
54. Zeiher AM, Drexler H, Wollschläger H, Just H (1991) Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 84: 1984-1992
55. Zeiher AM, Krause T, Schächinger V, Minners J, Moser E (1995) Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 91: 2345-2352
56. Zeiher AM, Schächinger V, Hohnloser SH, Saurbier B, Just H (1994) Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 89: 2525-2532